Purple Biotech Ltd - ADR Stock

$2.34

0.42% yesterday

Nasdaq, Jun 27, 10:00 pm CET

ISIN

US74638P1093

Symbol

PPBT

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Pharmaceuticals

Overview Dividends Analysts Charts News Strategies

Purple Biotech Ltd - ADR Stock price

$2.34

-237.66 99.03% 5Y

Nasdaq, Closing price Fri, Jun 27 2025

+0.01 0.42%

ISIN

US74638P1093

Symbol

PPBT

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Pharmaceuticals

Key metrics

Basic

Market capitalization

$6.9m

Enterprise Value

$-80.0k

Net debt

$-7.0m

Cash

$7.1m

Shares outstanding

555.9m

Valuation (TTM | estimate)

P/E

negative | -

P/S

- | -

EV/Sales

- | -

EV/FCF

0.01

P/B

39.86

Financial Health

Equity Ratio

88.72%

Return on Equity

-22.03%

ROCE

-24.41%

ROIC

Debt/Equity

0.00

Financials (TTM | estimate)

Revenue

$0.0 | $0.0

EBITDA

$-7.8m | -

EBIT

$-8.0m

Net Income

$-3.9m | -

Free Cash Flow

$-11.3m

Growth (TTM | estimate)

Revenue

- | -

EBITDA

63.45% | -

EBIT

62.93%

Net Income

79.05% | -

Free Cash Flow

40.55%

Margin (TTM | estimate)

Gross

EBITDA

- | -

EBIT

Net

- | -

Free Cash Flow

EPS

$-0.01

FCF per Share

$-0.02

Short interest

5.72%

Employees

Rev per Employee

As a Free StocksGuide user, you can view scores for all 6,914 stocks worldwide.

Get Started for Free Today

Purple Biotech Ltd - ADR Stock Analysis

Unlock Scores for Free

??

Financial data from Purple Biotech Ltd - ADR

Income Statement P&L | Balance Sheet | Cash Flow

Quarter TTM Annually

Mar '25		+/- %
Revenue	- -	- 100%
- Direct Costs	- -	- -
Gross Profit	- -	- -
- Selling and Administrative Expenses	2.85 2.85	39% 39% -
- Research and Development Expense	4.96 4.96	71% 71% -
EBITDA	-7.83 -7.83	63% 63% -
- Depreciation and Amortization	0.18 0.18	10% 10% -
EBIT (Operating Income) EBIT	-8.01 -8.01	63% 63% -
Net Profit	-3.93 -3.93	79% 79% -

In millions USD.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Subscribe Now

Purple Biotech Ltd - ADR Stock News

Neutral

GlobeNewsWire

●

5 days ago

Purple Biotech Highlights Significant Advantages of the Novel CAPTN-3 Tri-Specific Antibody Platform at the EACR 2025 Annual Congress

REHOVOT, Israel, June 23, 2025 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" or "the Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that seek to overcome tumor immune evasion and drug resistance, today announced the presentation of new preclinical data on its novel CAPTN-3 tri-specific antibody platform in a poster presentation at the 202...

Neutral

GlobeNewsWire

●

about one month ago

Purple Biotech Reports First Quarter 2025 Financial Results

Final CM24 Phase 2 data presented at AACR Annual Meeting 2025, strengthening patient selection strategy for CM24 Phase 2b study planned to be initiated in Second Half of 2025

Neutral

GlobeNewsWire

●

about 2 months ago

Purple Biotech Appoints Shai Lankry as Chief Financial Officer

U.S.-based Lankry brings over 20 years of financial leadership in biotech and healthcare with a proven track record of driving strategic growth, operational excellence, and capital market execution, including leading a U.S. IPO and M&A transaction

More Purple Biotech Ltd - ADR News

Company Profile

Purple Biotech Ltd. is a development stage pharmaceutical company, which engages in drug development. It operates through two segments: Oncology, and Pain & Hypertension. The Oncology segment includes NT219, a therapeutic candidate which is a small molecule that targets two signal transduction pathways which are involved in the development of cancer drug resistance mechanisms, and which is currently in the late pre-clinical stage of development. The Pain & Hypertension segment includes Consensi, a combination drug for the simultaneous treatment of two clinical conditions, pain caused by osteoarthritis and hypertension (high blood pressure), which can be pre-existing or caused by the treatment for osteoarthritis. The company was founded by John Paul Waymack on August 12, 1968 and is headquartered in Tel Aviv, Israel.

Head office	Israel
CEO	Gil Efron
Founded	1968
Website	purple-biotech.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now